Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Income (2016 - 2025)

Vanda Pharmaceuticals' Operating Income history spans 16 years, with the latest figure at -$40.4 million for Q4 2025.

  • On a quarterly basis, Operating Income fell 292.58% to -$40.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$151.2 million, a 271.79% decrease, with the full-year FY2025 number at -$151.2 million, down 271.79% from a year prior.
  • Operating Income hit -$40.4 million in Q4 2025 for Vanda Pharmaceuticals, down from -$31.3 million in the prior quarter.
  • Over the last five years, Operating Income for VNDA hit a ceiling of $12.4 million in Q2 2021 and a floor of -$41.0 million in Q1 2025.
  • Historically, Operating Income has averaged -$7.9 million across 5 years, with a median of -$6.5 million in 2023.
  • Biggest five-year swings in Operating Income: soared 8372.8% in 2021 and later tumbled 560.83% in 2024.
  • Tracing VNDA's Operating Income over 5 years: stood at $8.6 million in 2021, then fell by 23.24% to $6.6 million in 2022, then plummeted by 207.01% to -$7.1 million in 2023, then crashed by 44.9% to -$10.3 million in 2024, then crashed by 292.58% to -$40.4 million in 2025.
  • Business Quant data shows Operating Income for VNDA at -$40.4 million in Q4 2025, -$31.3 million in Q3 2025, and -$38.5 million in Q2 2025.